Knowledge Base

Life Sciences Lens

Step into the Future of Informed Decision-Making: How RIVAL Software Empowers Pharma and Biotech

In the high-stakes world of pharmaceuticals and biotechnology, making informed decisions about optimizing asset value,licensing deals, and portfolio management can mean the difference between groundbreaking success and costly missteps. Enter RIVAL, a cutting-edge valuation and licensing software designed specifically for the life sciences industry. This effective tool empowers pharma and biotech companies to navigate complex financial landscapes with precision and confidence. In this article, we’ll explore how RIVAL can be applied by companies in the sector and highlight its transformative benefits through real-world examples.

Life Sciences Lens

The Influence of Taxes on Deals in the Biotech and Pharma Industry: A Strategic Perspective for Optimizing Value

Licensing agreements are a fundamental component of the biotechnology and pharmaceutical industries, where biotech innovators often collaborate with large pharma companies to bring new therapies to market. These deals are critical for the development and commercialization of cutting-edge therapies, but one often-overlooked factor that can significantly influence the structure and value of these transactions is the tax regime of both the licensor (often a biotech company) and the licensee (the pharma company).

Life Sciences Lens

Unlocking Intrinsic Value for BioPharma Companies: The Key to Smarter Investments

In the complex and rapidly advancing world ofbiopharma, understanding a company's intrinsic value is crucial for investorsand stakeholders. Given the high levels of innovation and the long, often riskydevelopment pipelines, BioPharma companies present unique challenges when itcomes to valuation. To navigate this, savvy investors focus on intrinsic value,which reflects a company’s true worth based on fundamentals rather than marketsentiment.

Life Sciences Lens

Understanding Bucket vs Progressive Royalty Tiers in Pharma Licensing Deals

Mastering royalty structures in biotech and pharma licensing deals is critical for achieving the desired financial outcomes. Two key models to understand are bucket royalty tiers and progressive royalty tiers. These structures, based on estimated drug sales revenues, can dramatically affect your licensing agreement's economic value. Let's explore their nuances and impact.

Product

Valuation of an R&D stage pharmaceutical drug: what are the key value drivers?

The development of a pharmaceutical drug takes on average 10.5 years with average costs of development ranging from $314mio to $2.8billion . Every time during those development years, when money has to be spent on the development process questions come up relating to the current and future value of the project. This article will dive deeper into answering these questions.

RIVAL logo

Discoverhow RIVAL will support your funding efforts

Book your free consultation
© 2022 Avance. All rights reserved.
Terms & Conditions